Provided by Tiger Trade Technology Pte. Ltd.

Kazia Therapeutics Limited

11.01
-0.8700-7.32%
Post-market: 11.150.1400+1.27%19:30 EDT
Volume:374.29K
Turnover:4.17M
Market Cap:154.22M
PE:-1.61
High:11.75
Open:11.75
Low:10.83
Close:11.88
52wk High:17.40
52wk Low:4.86
Shares:14.01M
Float Shares:11.66M
Volume Ratio:1.18
T/O Rate:3.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.8190
EPS(LYR):-12.3849
ROE:-106.90%
ROA:-25.70%
PB:4.64
PE(LYR):-0.89

Loading ...

Kazia Therapeutics Limited Announces Proposed Public Offering

THOMSON REUTERS
·
Aug 28

Kazia Says Paxalisib Posts 100% Clinical Benefit Rate in Six-Patient Phase 1b Metastatic TNBC Study

Reuters
·
Aug 28

Kazia Therapeutics - Reports 83% Objective Response Rate in Six Patients

THOMSON REUTERS
·
Aug 28

Kazia Therapeutics - Phase 1B Study Enrollment Expected to Complete by July 2027, with Interim Clinical Updates Anticipated Throughout 2026 and 2027

THOMSON REUTERS
·
Aug 28

Kazia Therapeutics - All Patients Show Median 83% Reduction in Ctc Clusters, 51% in Exhausted T Cells

THOMSON REUTERS
·
Aug 28

Kazia Therapeutics - no Treatment-Related Serious Adverse Events Observed

THOMSON REUTERS
·
Aug 28

Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer

THOMSON REUTERS
·
Jul 28

Kazia Therapeutics Ltd : Btig Initiates Coverage with Buy Rating; Price Target $34

THOMSON REUTERS
·
Jul 01

Kazia Therapeutics CFO James Levine files initial beneficial ownership statement

Reuters
·
Jun 16

ADRs Advance; 111 Inc. Climbs 14%

Dow Jones
·
Jun 13

Kazia Therapeutics Initiated at Buy by Lake Street

Dow Jones
·
Jun 11

Kazia Therapeutics initiated with a Buy at Lake Street

TIPRANKS
·
Jun 11

Kazia Therapeutics director Ebru Davidson files initial beneficial ownership statement

Reuters
·
Jun 04

Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and Kazia Therapeutics (KZIA)

TIPRANKS
·
Jun 03

Kazia Therapeutics Names James Levine CFO

MT Newswires Live
·
Jun 02

Kazia Therapeutics names James Levine CFO effective June 1

Reuters
·
Jun 02

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

THOMSON REUTERS
·
Jun 02

Kazia expands Phase 1b paxalisib trial in advanced triple-negative breast cancer to 36 patients

Reuters
·
May 26

Kazia Therapeutics Expands Ongoing Phase 1B Trial of Paxalisib in Advanced Breast Cancer

THOMSON REUTERS
·
May 26

Kazia Therapeutics Ltd - Planned Enrollment in Phase 1B Trial to Increase From 12 to 36 Patients

THOMSON REUTERS
·
May 26